Skip to content Skip to sidebar Skip to footer
Subscribe Now
Viewpoints_Dr. Dale Christensen
VIEWPOINTS

PharmaShots Interview: TFF’s Dr. Dale Christensen Shares Insight on the Thin Film Freezing Technology

In an interview with PharmaShots, Dr. Dale Christensen, Ph.D., Director of Clinical Development at TFF Pharmaceuticals shared his views on the preliminary data from the P-I trial of inhalable tacrolimus powder formulation for Lung Transplant & its TFF technology Shots: TFF has developed an inhalable tacrolimus powder formulation that can be delivered directly to the lung via an inhaler bypassing…
September 15, 20210Comments

Read more

Viewpoints_James Graham
VIEWPOINTS

PharmaShots Interview: Recce Pharmaceuticals’ James Graham Shares Insight on the P-I/II Clinical Trial of RECCE 327 (R327) for Infected Burn Wounds

In an interview with PharmaShots, James Graham, CEO of Recce Pharmaceuticals shared his views on the multiple patient dosing in P-I/II clinical trial of RECCE 327 (R327) for the treatment of infected burn wounds. Shots: The multiple patients have been dosed in P-I/II trial evaluates the effectiveness & safety of RECCE 327 in 30 patients (10 will receive RECCE 327…
September 14, 20210Comments

Read more

Viewpoints_Dr. Ian Walters
VIEWPOINTS

PharmaShots Interview: Portage Biotech’s Dr. Ian Walters Shares Insight on the Data of INT230-6 Presented at ASCO 2021

In an interview with PharmaShots, Dr. Ian Walters, CEO of Portage Biotech shared his views on the interim data from the P-II IT-01 trial evaluates the safety and efficacy of INT230-6 as both a monotherapy and in combination with pembrolizumab or ipilimumab in solid tumors Shots: The P-II IT-01 trial evaluates the safety & efficacy of INT230-6 as monothx. & in…
September 13, 20210Comments

Read more

Exclusive_Kelly Pokuta1_April Kunze2_2021
EXCLUSIVE

Exclusive Interview with PharmaShots: Kelly Pokuta and April Kunze of Prime Therapeutics Share Insight on MedDrive, a Medical Drug Management Program

In an exclusive interview with PharmaShots, Kelly Pokuta, Vice President of Pharmaceutical Trade Relations, and April Kunze, Senior Director, Clinical Formulary Development & Trend Management Strategy at Prime therapeutics share their views on the MedDrive as a first-of-its-kind medical drug management program uniquely aligned with its Blue Plan clients. Shots: Prime introduced the first-of-its-kind medical drug management solution with…
September 7, 20210Comments

Read more

Viewpoints_Paula Ragan
VIEWPOINTS

Pharmashots Interview: Paula Ragan Shares Insights on the Data of Mavorixafor in Combination with Ibrutinib Presented at 2021 EHA Annual Congress

In an interview with PharmaShots, Paula Ragan, Ph.D., President, and Chief Executive Officer at X4 Pharmaceuticals shared her views on preliminary efficacy and safety data of Mavorixafor + Ibrutinib in an ongoing P-Ib study to treat waldenström's macroglobulinemia Shots: The ongoing P-Ib clinical trial evaluates the safety & efficacy of mavorixafor + ibrutinib in patients with WM with both MYD88 &…
September 3, 20210Comments

Read more

Viewpoints_Michael Dale
VIEWPOINTS

PharmaShots Interview: Abbott’s Michael Dale Shares Insight on the CE Mark for the Next-Generation Navitor TAVI System

In an interview with PharmaShots, Michael Dale, Senior Vice President of the Structural Heart division at Abbott shared his views on the Navitor's approval in the EU for patients with severe aortic stenosis who are at high or extreme surgical risk for open-heart surgery. Shots: Abbott has received CE Mark approval for its latest-generation transcatheter aortic…
September 3, 20210Comments

Read more

Insights+ Key Biosimilars Events of August 2021
INSIGHTS+

Insights+ Key Biosimilars Events of August 2021

Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potency Biosimilars are expected to be a cost-effective alternative to the high-priced branded biologics, offering significant and much-needed cost savings to both payers and the patients During the month of August, Samsung Bioepis Byooviz (biosimilar, ranibizumab) received EC's…
September 2, 20210Comments

Read more

Viewpoints_Rami Levin
VIEWPOINTS

PharmaShots Interview: Saniona’s Rami Levin Shares Insight on Tesomet for Hypothalamic Obesity

In an interview with PharmaShots, Rami Levin, Chief Executive Officer at Saniona shared his views on the US FDA's Orphan Drug Designation (ODD) to Tesomet for the treatment of hypothalamic obesity (HO) and discuss its role in the company's continued pipeline progress. Shots: Saniona reported that the FDA has granted orphan drug designation to Tesomet for the…
August 27, 20210Comments

Read more

Sign Up to Our Newsletter

Be the first to know the latest updates

[mc4wp_form id="13387" element_id="style-1"]